Elliot Stieglitz, MD
Associate Professor
Pediatrics
School of Medicine

We have also shown that DNA methylation profiling can identify patients most likely to experience favorable outcomes.

We recently completed a clinical trial through the Children's Oncology Group for patients with relapsed and refractory JMML. This trial tested the safety and efficacy of the oral MEK inhibitor, trametinib and met its primary objective. This trial was based on extensive pre-clinical testing and a strong genomic rationale. This trial marks an important step towards more effectively treating patients with Ras driven leukemia using targeted agents.

Our current trial (NCT05849662) risk-stratifies patients with newly diagnosed JMML to receive different intensities of therapy based on the number of mutations and DNA methylation signatures at diagnosis. It also combines trametinib with standard-of-care therapy for newly diagnosed patients.

• In Vivo and In Vitro Chemical Synthetic Lethality of ABHD17 and MEK Inhibition in NRAS -Mutant Acute Myeloid Leukemia.
  Blood 2024 Matthew Decker, Benjamin J Huang, Tim Ware, Christopher Boone, Michelle Tang, Aishwarya Ballapuram, Julia Ybarra, Katrine Taran, Marcos Amendáriz, Camille Leung, Max Harris, Elliot Stieglitz, Micah …
• Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations.
  Blood 2024 Bogdan Popescu, Madison Piao, Sydney Abelson, Carolina E. Morales, Khadija Yousuf, Jose M. Rivera, Cheryl A C Peretz, Elliot Stieglitz, Catherine C. Smith
• Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.
  Frontiers in immunology 2024 Johns C, Erickson C, Jacobs A, Moon J, Baggott C, Dagher R, Nadel H, Balagtas J, Aftandilian C, Ramakrishna S, Lacayo N, Davis KL, Stieglitz E, Schultz L
• Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia.
  Research square 2024 Zheng H, Zhao P, Tan Z, Yu WM, Werner J, Stieglitz E, Porter C, Chandrakasan S, Wechsler D, Mendez-Ferrer S, Qu CK
• LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.
  Haematologica 2024 Wintering A, Hecht A, Meyer J, Wong EB, Hübner J, Abelson S, Feldman K, Kennedy VE, Peretz CAC, French DL, Maguire JA, Jobaliya C, Vasquez MR, Desai S, Dulman R, Nemecek E, Haines H, Hammad M, El …
• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
  bioRxiv : the preprint server for biology 2024 Kasap C, Izgutdina A, Patiño-Escobar B, Kang A, Chilakapati N, Akagi N, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Wicaksono G, …
• Risk-stratified Treatment for Pediatric Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia.
  The Hematologist 2024 Elliot Stieglitz, Lauren Pommert
• Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
  Pediatric blood & cancer 2024 Feldman K, Aaronson K, Gu T, Ige K, Southworth E, Sanchez L, Stieglitz E
• Preclinical Development and Characterization of Humanized Anti-CD72 Nanobody Chimeric Antigen Receptor T Cells for B Cell Malignancies.
  Transplantation and Cellular Therapy 2024 William C. Temple, Adila Izgutdina, Matthew A. Nix, Benjamin J. Huang, Paul Phojanakong, Juan Antonio Camara Serrano, Fernando Salangsang, Veronica Steri, Simayijiang Xirenayi, Elliot Stieglitz, Arun …
• Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
  Cancers 2024 Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li HT, Liang G, Leong R, Brown PA, Kaplan J, Schafer ES, Slone T, Pauly M, Chang BH, Stieglitz E, Wayne AS, Hijiya N, Bhojwani D
• Too many white cells-TAM, JMML, or something else?
  Hematology. American Society of Hematology. Education Program 2023 Satty A, Stieglitz E, Kucine N
• Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group.
  Blood 2023 Elliot Stieglitz, Alex Lee, Steven P. Angus, Christopher Davis, Donald Barkauskas, David Hall, Scott C. Kogan, Julia Meyer, Steven D. Rhodes, Xiaoling Xuei, Kevin Shannon, Mignon L. Loh, Elizabeth Fox…
• Mediator Kinase/CDK8 Inhibition As a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia.
  Blood 2023 Timothy T. Ferng, Samantha M. Pintar, Vanessa E. Kennedy, Theodore C. Tarver, Shaheen Kabir, Veronica Steri, Juan Antonio Camara Serrano, Fernando Salangsang, Paul Phojanakong, Juwita Hübner, Carolina…
• RAS MULTI(ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models.
  Blood 2023 Bogdan Popescu, Elliot Stieglitz, Catherine C. Smith
• Risk Stratified Treatment for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase 1/2 Non-Randomized Study of Trametinib and Azacitidine with or without Chemotherapy.
  Blood 2023 Elliot Stieglitz, Yueh-Yun Chi, Bill H. Chang, Sarah K. Tasian, Marielle Yohe, Christopher C Dvorak, Erica Southworth, Janel R. Long-Boyle, Jessica Van Ziffle, Zied Abdullaev, Roy Leong, Alan S. Wayne…
• Threshold Attenuation of Perk Signaling Is Sufficient to Overcome RAS-Mediated FLT3 Inhibitor Resistance.
  Blood 2023 Cheryl A C Peretz, Elaine Tran, Bogdan Popescu, Vanessa E. Kennedy, Tanya Kumar, Lisa McGary, Natalie Tantisira, Eric Wong, Jose M. Rivera, Simayijiang Xirenayi, Elliot Stieglitz, Catherine C. Smith, …
• Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
  Journal for immunotherapy of cancer 2023 Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JAC, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP
• Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
  Cell reports. Medicine 2023 Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC
• The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy.
  American journal of medical genetics. Part A 2023 Pierpont EI, Bennett AM, Schoyer L, Stronach B, Anschutz A, Borrie SC, Briggs B, Burkitt-Wright E, Castel P, Cirstea IC, Draaisma F, Ellis M, Fear VS, Frone MN, Flex E, Gelb BD, Green T, Gripp KW, …
• Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.
  Cancer reports (Hoboken, N.J.) 2023 Shumock SS, Temple WC, Marinoff A, Aaronson K, Southworth E, Xirenayi S, Lee AG, Leung SG, Sweet-Cordero EA, Hermiston M, Higham C, Stieglitz E
• Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target.
  Nature cancer 2023 Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano …
• Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay.
  JCO precision oncology 2023 Stieglitz E, Gu CJ, Richardson M, Kita R, Santaguida MT, Ali KA, Strachan DC, Dhar A, Yam G, Anderson W, Anderson E, Hübner J, Tasian SK, Loh ML, Lacher MD
• P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE.
  HemaSphere 2023 Jeffrey Rubnitz, Ghayas C. Issa, Eytan M. Stein, Neerav Shukla, Wendy Stock, Andrius Žucenka, Sajad Khazal, Nandita Khera, Elliot Stieglitz, Jeremy Rubinstein, Galit Rosen, Rachel Ghiraldi, Huy Van …
• P985: CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA.
  HemaSphere 2023 Juwita Huebner, Sherin Xirenayi, Jose Rivera, Bonell Patiño Escobar, Alex G Lee, Kamal Mandal, Ernesto Diaz-Flores, Arun Wiita, Elliot Stieglitz
• P998: TRETINOIN AND CALCITRIOL ENHANCE TREATMENT REGIMENS FOR JUVENILE MYELOMONOCYTIC LEUKEMIA IN EX VIVO DRUG SENSITIVITY ASSAYS.
  HemaSphere 2023 Elliot Stieglitz, Christine Gu, Anukriti Dhar, Juwita Huebner, Kamran Ali, Markus Lacher
• Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.
  Pediatric blood & cancer 2023 Marinoff AE, Aaronson K, Agrawal AK, Braun BS, Golden C, Huang BJ, Michlitsch J, Southworth E, Thrall A, Vo KT, Stieglitz E
• Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
  Molecular therapy : the journal of the American Society of Gene Therapy 2023 Pasupuleti SK, Chao K, Ramdas B, Kanumuri R, Palam LR, Liu S, Wan J, Annesley C, Loh ML, Stieglitz E, Burke MJ, Kapur R
• Targeting Arg-1 and PD-L1 in M2-Tumor Associated Macrophages Impairs Juvenile Myelomonocytic Leukemia (JMML) Cell Proliferation and Migration.
  Proceedings of IMPRS 2023 Kailah Young, Santhosh Kumar Pasupuleti, Elliot Stieglitz, Reuben Kapur
• LNK/SH2B3 As a Novel Driver in Juvenile Myelomonocytic Leukemia.
  Blood 2022 Astrid Wintering, Anna Hecht, Julia Meyer, Eric Brandon Wong, Deborah L French, Jean Ann Maguire, Chintan Jobaliya, Marta Rojas Vasquez, Sunil J. Desai, Robin Yates Dulman, Eneida R. Nemecek, Farid F …
• MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
  Neuro-oncology 2022 de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ, …
• Classification of rare pediatric myeloid neoplasia-Quo vadis?
  Leukemia 2022 Niemeyer CM, Rudelius M, Shimamura A, Flotho C, Hasle H, Stieglitz E, Strahm B, Godley LA, Weinberg OK, Orazi A, Calvo KR
• Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
  European journal of cancer (Oxford, England : 1990) 2022 Pearson AD, Allen C, Fangusaro J, Hutter C, Witt O, Weiner S, Reaman G, Russo M, Bandopadhayay P, Ahsan S, Barone A, Barry E, de Rojas T, Fisher M, Fox E, Bender JG, Gore L, Hargrave D, Hawkins D, …
• Clinical parameter-based prediction of DNA methylation classification generates a prediction model of prognosis in patients with juvenile myelomonocytic leukemia.
  Scientific reports 2022 Imaizumi T, Meyer J, Wakamatsu M, Kitazawa H, Murakami N, Okuno Y, Yoshida T, Sajiki D, Hama A, Kojima S, Takahashi Y, Loh M, Stieglitz E, Muramatsu H
• Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy.
  Cold Spring Harbor molecular case studies 2022 Smith SM, Lee A, Tong S, Leung S, Hongo H, Rivera J, Sweet-Cordero A, Michlitsch J, Stieglitz E
• Cytomorphologic features of pediatric-type follicular lymphoma on fine needle aspiration biopsy: case series and a review of the literature.
  Journal of the American Society of Cytopathology 2022 Lu KL, Menke JR, Ng D, Ruiz-Cordero R, Marinoff A, Stieglitz E, Gollapudi S, Singh K, Ohgami RS, Vohra P
• Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.
  Molecular therapy : the journal of the American Society of Gene Therapy 2022 Ramdas B, Yuen LD, Palam LR, Patel R, Pasupuleti SK, Jideonwo V, Zhang J, Maguire C, Wong E, Kanumuri R, Zhang C, Sandusky G, Chan RJ, Zhang C, Stieglitz E, Haneline L, Kapur R
• Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm.
  Blood advances 2022 Miltiadous O, Petrova-Drus K, Kaicker S, Mathew S, Kluk M, Geyer JT, Rodriguez-Sanchez I, Bouvier N, Inghirami G, Stieglitz E, Khedoudja N, Benayed R, Richardson M, Anderson W, Benhamida J, You D, …
• JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β.
  Blood advances 2022 Yan Y, Dong L, Chen C, Bunting KD, Li Q, Stieglitz E, Loh ML, Qu CK
• Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.
  Haematologica 2022 Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney…
• Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia.
  Blood advances 2021 Kitazawa H, Okuno Y, Muramatsu H, Aoki K, Murakami N, Wakamatsu M, Suzuki K, Narita K, Kataoka S, Ichikawa D, Hamada M, Taniguchi R, Kawashima N, Nishikawa E, Narita A, Nishio N, Hama A, Loh ML, …
• Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.
  Pediatric blood & cancer 2021 Wintering A, Smith S, Fuh B, Rangaswami A, Dahl G, Chien M, Gruber TA, Dang J, Li LS, Lenzen A, Savelli S, Dvorak CC, Agrawal AK, Stieglitz E
• Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.
  Blood advances 2021 Wintering A, Dvorak CC, Stieglitz E, Loh ML
• Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia.
  Blood 2021 Bogdan Popescu, Carlos Stahlhut, Theodore C. Tarver, Timothy T. Ferng, Cheryl Peretz, Sydney Wishner, Paul Phojanakong, Veronica Steri, Eric B. Wong, Jose M. Rivera, Elliot Stieglitz, Catherine C. …
• MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521.
  Blood 2021 Elliot Stieglitz, Mignon L. Loh, Julia Meyer, Chujing Zhang, Donald A Barkauskas, David Hall, Elizabeth Fox, Brenda J. Weigel
• Targeting M2-Tumor Associated Macrophages By Arginase-1 and PD-L1 in Regulating Juvenile Myelomonocytic Leukemia (JMML) Development and Relapse.
  Blood 2021 Santhosh Kumar Pasupuleti, Baskar Ramdas, Kai Yang, Chujing Zhang, Elliot Stieglitz, Reuben Kapur
• Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
  Blood advances 2021 Morales CE, Stieglitz E, Kogan SC, Loh ML, Braun BS
• NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.
  Journal of pediatric hematology/oncology 2021 Behnert A, Lee AG, Young EP, Breese MR, Leung SG, Behroozfard I, Maruffi M, Sweet-Cordero EA, Dvorak CC, Chu J, Stieglitz E
• Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples.
  Leukemia 2021 Behnert A, Meyer J, Parsa JY, Hechmer A, Loh ML, Olshen A, de Smith AJ, Stieglitz E
• Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL.
  Cancer discovery 2021 Nix MA, Mandal K, Geng H, Paranjape N, Lin YT, Rivera JM, Marcoulis M, White KL, Whitman JD, Bapat SP, Parker KR, Ramirez J, Deucher A, Phojanokong P, Steri V, Fattahi F, Hann BC, Satpathy AT, Manglik…
• Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.
  Nature communications 2021 Kennedy AL, Myers KC, Bowman J, Gibson CJ, Camarda ND, Furutani E, Muscato GM, Klein RH, Ballotti K, Liu S, Harris CE, Galvin A, Malsch M, Dale D, Gansner JM, Nakano TA, Bertuch A, Vlachos A, Lipton …
• Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.
  Cancer discovery 2021 Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee …
• Targeting the Ras pathway in pediatric hematologic malignancies.
  Current opinion in pediatrics 2020 Pikman Y, Stieglitz E
• Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome.
  Blood 2020 Alyssa L. Kennedy, Kasiani C. Myers, James Bowman, Christopher J. Gibson, Gwen M. Muscato, Robert Klein, Kaitlyn Ballotti, Nicholas Camarda, Elissa M. Furutani, Chad E. Harris, Shanshan Liu, Ashley …
• Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia.
  Blood 2020 Astrid Behnert, Julia Meyer, Jahan-Yar Parsa, Aaron Hechmer, Mignon L. Loh, Adam B. Olshen, Adam J. de Smith, Elliot Stieglitz
• Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature.
  JCO precision oncology 2020 Levinson A, Lee AG, Martell HJ, Breese MR, Zaloudek C, Van Ziffle J, Laguna B, Leung SG, Chen MD, Chen LM, Pfeil J, Ladwig NR, Shah AT, Behroozfard I, Rao AA, Salama SR, Sweet-Cordero EA, Stieglitz E
• International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Schönung M, Meyer J, Nöllke P, Olshen AB, Hartmann M, Murakami N, Wakamatsu M, Okuno Y, Plass C, Loh ML, Niemeyer CM, Muramatsu H, Flotho C, Stieglitz E, Lipka DB
• Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
  Pediatric blood & cancer 2020 Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK
• Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant.
  Bone marrow transplantation 2020 Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Margossian SP, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Stieglitz E, Yeager N, O'Reilly RJ, Brentjens RJ, Jan Boelens J, …
• Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform.
  Scientific reports 2019 Dueck ME, Lin R, Zayac A, Gallagher S, Chao AK, Jiang L, Datwani SS, Hung P, Stieglitz E
• The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
  Pediatric blood & cancer 2019 Friend BD, Bailey-Olson M, Melton A, Shimano KA, Kharbanda S, Higham C, Winestone LE, Huang J, Stieglitz E, Dvorak CC
• DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation.
  Blood 2019 Julia Meyer, Maximillian Schönung, Christian Flotho, Adam B. Olshen, Mark Hartmann, Christoph Plass, Yusuke Okuno, Yoshiyuki Takahashi, Norihiro Murakami, Manabu Wakamatsu, Mignon L. Loh, Charlotte M.…
• In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies.
  Blood 2019 Matthew Nix, Yu-Hsiu T. Lin, Huimin Geng, Makeba Marcoulis, Paul Phojanakong, Donghui Wang, Veronica Steri, Jeffrey Whitman, Sagar Bapat, Elliot Stieglitz, Anne Deucher, Kristie L White, Byron C Hann,…
• Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
  Leukemia 2019 Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E
• Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
  Pediatric blood & cancer 2019 Hecht A, Meyer J, Chehab FF, White KL, Magruder K, Dvorak CC, Loh ML, Stieglitz E
• Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.
  Genes, chromosomes & cancer 2019 de Smith AJ, Lavoie G, Walsh KM, Aujla S, Evans E, Hansen HM, Smirnov I, Kang AY, Zenker M, Ceremsak JJ, Stieglitz E, Muskens IS, Roberts W, McKean-Cowdin R, Metayer C, Roux PP, Wiemels JL
• Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.
  American journal of human genetics 2019 Capri Y, Flex E, Krumbach OHF, Carpentieri G, Cecchetti S, Lißewski C, Rezaei Adariani S, Schanze D, Brinkmann J, Piard J, Pantaleoni F, Lepri FR, Goh ES, Chong K, Stieglitz E, Meyer J, Kuechler A, …
• Genomic subtyping and therapeutic targeting of acute erythroleukemia.
  Nature genetics 2019 Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, …
• DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia: An International Collaborative Analysis and Development of a Common Diagnostic Platform.
  Blood 2018 Maximilian Schoenung, Elliot Stieglitz, Hideki Muramatsu, Norihiro Murakami, Mark Hartmann, Manuel Wiesenfarth, Yusuke Okuno, Adam B. Olshen, Christoph Plass, Mignon L. Loh, Charlotte Niemeyer, …
• Germline GAB2 Mutations in Childhood Acute Lymphoblastic Leukemia.
  Blood 2018 Adam J de Smith, Geneviève Lavoie, Kyle M Walsh, Sumeet Aujla, Erica Evans, Helen M Hansen, Ivan Smirnov, Alice Y Kang, Martin Zenker, John J Ceremsak, Elliot Stieglitz, Roberta McKean-Cowdin, …
• Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia.
  Blood 2018 Andrew E. Place, Traci M. Blonquist, Elliot Stieglitz, Todd M Cooper, Lia Gore, Richard Aplenc, Mignon L. Loh, Melinda Pauly, Rachel E. Rau, Michael J. Burke, Julia Etchin, A. Thomas Look, Maria Luisa…
• Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.
  Leukemia 2018 Kong G, You X, Wen Z, Chang YI, Qian S, Ranheim EA, Letson C, Zhang X, Zhou Y, Liu Y, Rajagopalan A, Zhang J, Stieglitz E, Loh M, Hofmann I, Yang D, Zhong X, Padron E, Zhou L, Pear WS, Zhang J
• ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients.
  Journal of pediatric hematology/oncology 2018 Stieglitz E, Dinh T, Phelps AS, Pampaloni MH, Olshen AB, Robbins E
• Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
  Pediatric blood & cancer 2018 Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML
• Abstract 26: RUNX1 as a transcriptional target of activated Shp2 (PTPN11) in juvenile myelomonocytic leukemia.
  Leukemia 2017 Elisa Dorantes-Acosta, Hui Huang, Sara P. Garcia, Elliot Stieglitz, Mignon Loh, Guo-Cheng Yuan, Alan B. Cantor
• Dysregulation of the transcription factor runx1 in juvenile myelomonocytic leukemia.
  Experimental Hematology 2017 Alan Cantor, Elisa Dorantes-Costa, Hui Huang, Sara Garcia, Elliot Stieglitz, Mignon Loh, Guo-Cheng Yuan
• Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
  Blood 2017 Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, …
• A Risk Stratified Treatment Algorithm for Patients with Juvenile Myelomonocytic Leukemia.
  2017 Ashley Koegel, Elliot Stieglitz
• International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.
  Analytical chemistry 2017 Whale AS, Devonshire AS, Karlin-Neumann G, Regan J, Javier L, Cowen S, Fernandez-Gonzalez A, Jones GM, Redshaw N, Beck J, Berger AW, Combaret V, Dahl Kjersgaard N, Davis L, Fina F, Forshew T, …
• RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia.
  Blood 2016 Elisa Dorantes Acosta, Hui Huang, Sara P. Garcia, Elliot Stieglitz, Mignon L. Loh, G C Yuan, Alan B. Cantor
• The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia.
  Blood 2016 Ilaria Iacobucci, Ji Wen, Manja Meggendorfer, Catherine Carmichael, John K Choi, Katherine Masih, Yongjin Li, Debbie Payne, Daisuke Tomizawa, Nobutaka Kiyokawa, Laura J. Janke, Thomas B. Alexander, …
• Germline RRAS2 mutations are not associated with Noonan syndrome.
  Journal of medical genetics 2016 Ceremsak JJ, Yu A, Esquivel E, Lissewski C, Zenker M, Loh ML, Stieglitz E
• Pediatric MDS: GATA screen the germline.
  Blood 2016 Stieglitz E, Loh ML
• Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia.
  Nature genetics 2016 Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T,…
• Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
  Pediatric blood & cancer 2014 Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, Emanuel PD, Widemann BC, Cheng JW, Jayaprakash N, Balis FM, Castleberry RP, Bunin NJ, Loh ML, Cooper TM
• Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia.
  Blood 2014 Elliot Stieglitz, Camille B Troup, Laura C Gelston, Eric D Chow, Kristie B Yu, Jon Akutagawa, Amaro N Taylor-Weiner, Y. Lucy Liu, Peter D Emanuel, Benjamin S Braun, Robert B. Gerbing, Todd A. Alonzo, …
• Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
  Blood 2014 Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML
• Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.
  Blood 2014 Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML
• Pulmonary coccidiomycosis masquerading as refractory metastatic Ewing sarcoma.
  Journal of pediatric hematology/oncology 2014 Stieglitz E, Hsiang MS, Simko JP, Hirose S, Goldsby RE
• Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia.
  Blood 2013 Elliot Stieglitz, Y. Lucy Liu, Peter D. Emanuel, Robert P. Castleberry, Todd Michael Cooper, Kevin Shannon, Mignon L. Loh
• Genetic predispositions to childhood leukemia.
  Therapeutic advances in hematology 2013 Stieglitz E, Loh ML